MetaVia Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About MetaVia Inc
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
/ 
Frequently asked questions
To buy MetaVia Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for MetaVia Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for MetaVia Inc is MTVA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
MetaVia Inc has its primary listing on NASDAQ (Small cap). You can trade MetaVia Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, MetaVia Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include MetaVia Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like MetaVia Inc.